Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hui, Zhang, Yuntao, Huang, Baoying, Deng, Wei, Quan, Yaru, Wang, Wenling, Xu, Wenbo, Zhao, Yuxiu, Li, Na, Zhang, Jin, Liang, Hongyang, Bao, Linlin, Xu, Yanfeng, Ding, Ling, Zhou, Weimin, Gao, Hong, Liu, Jiangning, Niu, Peihua, Zhao, Li, Zhen, Wei, Fu, Hui, Yu, Shouzhi, Zhang, Zhengli, Xu, Guangxue, Li, Changgui, Lou, Zhiyong, Xu, Miao, Qin, Chuan, Wu, Guizhen, Gao, George Fu, Tan, Wenjie, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275151/
https://www.ncbi.nlm.nih.gov/pubmed/32778225
http://dx.doi.org/10.1016/j.cell.2020.06.008
Descripción
Sumario:The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

Ejemplares similares